398 related articles for article (PubMed ID: 32980406)
1. Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
Ugurel OM; Mutlu O; Sariyer E; Kocer S; Ugurel E; Inci TG; Ata O; Turgut-Balik D
Int J Biol Macromol; 2020 Nov; 163():1687-1696. PubMed ID: 32980406
[TBL] [Abstract][Full Text] [Related]
2. Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase.
White MA; Lin W; Cheng X
J Phys Chem Lett; 2020 Nov; 11(21):9144-9151. PubMed ID: 33052685
[TBL] [Abstract][Full Text] [Related]
3. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.
Panera N; Tozzi AE; Alisi A
Drugs; 2020 Jul; 80(10):941-946. PubMed ID: 32451923
[TBL] [Abstract][Full Text] [Related]
4. Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.
Sharma K; Morla S; Goyal A; Kumar S
Life Sci; 2020 Oct; 259():118169. PubMed ID: 32738360
[TBL] [Abstract][Full Text] [Related]
5. SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts.
Shu T; Huang M; Wu D; Ren Y; Zhang X; Han Y; Mu J; Wang R; Qiu Y; Zhang DY; Zhou X
Virol Sin; 2020 Jun; 35(3):321-329. PubMed ID: 32500504
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.
Ahmad S; Waheed Y; Ismail S; Bhatti S; Abbasi SW; Muhammad K
Molecules; 2021 Mar; 26(5):. PubMed ID: 33800013
[TBL] [Abstract][Full Text] [Related]
7. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
8. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
Wang J
J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
10. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
11. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
Khan A; Khan M; Saleem S; Babar Z; Ali A; Khan AA; Sardar Z; Hamayun F; Ali SS; Wei DQ
Interdiscip Sci; 2020 Sep; 12(3):335-348. PubMed ID: 32617855
[TBL] [Abstract][Full Text] [Related]
12. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
13. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
14. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
15. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase.
Newman JA; Douangamath A; Yadzani S; Yosaatmadja Y; Aimon A; Brandão-Neto J; Dunnett L; Gorrie-Stone T; Skyner R; Fearon D; Schapira M; von Delft F; Gileadi O
Nat Commun; 2021 Aug; 12(1):4848. PubMed ID: 34381037
[TBL] [Abstract][Full Text] [Related]
16. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.
Freidel MR; Armen RS
PLoS One; 2021; 16(2):e0246181. PubMed ID: 33596235
[TBL] [Abstract][Full Text] [Related]
17. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL
Chitranshi N; Gupta VK; Rajput R; Godinez A; Pushpitha K; Shen T; Mirzaei M; You Y; Basavarajappa D; Gupta V; Graham SL
J Transl Med; 2020 Jul; 18(1):278. PubMed ID: 32646487
[TBL] [Abstract][Full Text] [Related]
18. The stalk domain of SARS-CoV-2 NSP13 is essential for its helicase activity.
Yue K; Yao B; Shi Y; Yang Y; Qian Z; Ci Y; Shi L
Biochem Biophys Res Commun; 2022 Apr; 601():129-136. PubMed ID: 35245742
[TBL] [Abstract][Full Text] [Related]
19. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists.
Yuen CK; Lam JY; Wong WM; Mak LF; Wang X; Chu H; Cai JP; Jin DY; To KK; Chan JF; Yuen KY; Kok KH
Emerg Microbes Infect; 2020 Dec; 9(1):1418-1428. PubMed ID: 32529952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
